ACADIA Pharmaceuticals CEO Stephen Davis Sells 7,806 Shares in Recent Transaction
May 5, 2023
Trending News ☀️
ACADIA ($NASDAQ:ACAD) Pharmaceuticals Inc. is a biopharmaceutical company based in San Diego, California. The company focuses on developing and commercializing drugs to treat central nervous system disorders, including Parkinson’s disease and Alzheimer’s disease. On Monday, CEO Stephen Davis of ACADIA Pharmaceuticals Inc. disposed of 7,806 shares of the company’s stock in a transaction.
Whether or not this is a sign of a potential increase in share price remains to be seen. Nevertheless, Davis’ decision to divest 7,806 shares of his company’s stock shows his confidence in the company’s future prospects.
Market Price
On Thursday, the stock opened at $21.1 and closed at $21.6, which represent a 1.7% increase from the previous closing price of $21.2. While the exact reason for the sale was not disclosed, it is likely that Davis is trying to make a profit from the increasing stock price. This comes at a time when ACADIA PHARMACEUTICALS has seen a surge in its share price due to positive news regarding the development of its Parkinson’s disease drug. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Acadia Pharmaceuticals. More…
| Total Revenues | Net Income | Net Margin |
| 517.24 | -215.97 | -41.8% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Acadia Pharmaceuticals. More…
| Operations | Investing | Financing |
| -114.03 | 73.24 | 8.2 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Acadia Pharmaceuticals. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 587.81 | 187.4 | 2.47 |
Key Ratios Snapshot
Some of the financial key ratios for Acadia Pharmaceuticals are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 15.1% | – | -43.2% |
| FCF Margin | ROE | ROA |
| -22.0% | -33.8% | -23.8% |
Analysis
At GoodWhale, we conducted an analysis of ACADIA PHARMACEUTICALS‘ fundamentals. Our Star Chart showed that ACADIA PHARMACEUTICALS is strong in asset and growth, but weak in dividend and profitability. The company has an intermediate health score of 4/10 with regards to its cashflows and debt, which means that it is likely to sustain future operations in times of crisis. Further, we classified ACADIA PHARMACEUTICALS as a ‘cheetah’ type of company – one that achieved high revenue or earnings growth but is considered less stable due to lower profitability. Investors who are looking for a company with high growth potential and are comfortable with lower profits may be interested in investing in ACADIA PHARMACEUTICALS. Such investors should weigh the pros and cons of the company’s fundamentals and risks associated with investing in such company. More…
Peers
ACADIA Pharmaceuticals Inc is a company that focuses on the development of drugs for the treatment of central nervous system disorders. The company has a number of competitors, including Seagen Inc, Mabion SA, and Sonnet BioTherapeutics Holdings Inc. Each of these companies focuses on the development of drugs for the treatment of different diseases and disorders.
– Seagen Inc ($NASDAQ:SGEN)
Seagen Inc. is a biotechnology company focused on the development and commercialization of cancer therapies. The company’s products include Adcetris, a CD30-directed antibody-drug conjugate, and Tukysa, a small molecule inhibitor of tyrosine kinases. Seagen Inc. has a market cap of $23.95 billion and a return on equity of -14.89%. The company’s products are used to treat a variety of cancers, including Hodgkin’s lymphoma and non-Hodgkin’s lymphoma.
– Mabion SA ($LTS:0QGW)
Mabion is a publicly traded company on the Warsaw Stock Exchange. The company’s market capitalization is $345.53 million as of 2022. The company’s return on equity is 23.01%. Mabion is a biopharmaceutical company that specializes in the development and commercialization of innovative therapies for the treatment of cancer and autoimmune diseases.
– Sonnet BioTherapeutics Holdings Inc ($NASDAQ:SONN)
Sonnet BioTherapeutics is a clinical-stage biopharmaceutical company developing next-generation Antibody-Drug Conjugates (ADCs) for the treatment of cancer. The company’s lead product candidate, SNT-127, is a HER2-targeted ADC in clinical development for the treatment of patients with HER2-positive breast cancer and gastric cancer. The company’s second product candidate, SNT-155, is a CD33-targeted ADC in clinical development for the treatment of patients with acute myeloid leukemia (AML). Sonnet BioTherapeutics is headquartered in New York, New York.
As of 2022, Sonnet BioTherapeutics has a market cap of 5.11M and a Return on Equity of -393.11%. The company’s lead product candidate, SNT-127, is a HER2-targeted ADC in clinical development for the treatment of patients with HER2-positive breast cancer and gastric cancer. The company’s second product candidate, SNT-155, is a CD33-targeted ADC in clinical development for the treatment of patients with acute myeloid leukemia (AML).
Summary
ACADIA Pharmaceuticals Inc. has recently seen its CEO Stephen Davis sell off 7,806 shares of the company’s stock. This is a major indication that investors should keep an eye on the stock as activity from insiders can be a major indicator of the company’s future performance. Analysts suggest that investors should research the company’s financials, revenue growth, and competitive positioning to have a better understanding of the potential returns this stock could provide.
Furthermore, investors should also monitor the company’s news for any other potential indicators of future successes or downfalls. Overall, ACADIA Pharmaceuticals Inc. currently looks like an interesting stock to watch and could be worth further investigation.
Related Posts
Recent Posts
Investing Everyone Can Do.
Investing shouldn’t be exclusive to a select few. We believe everyone should have the opportunity to grow their wealth. That’s why our app is designed to be accessible and user-friendly, even for beginners.
